Vivani Medical Mergers and Acquisitions Presentation Deck
Disclaimers
The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by
those sections. All statements in this release that are not based on historical fact are "forward looking statements. These statements may be identified by
words such as "estimates," "anticipates," "projects," "plans" or "planned," "strategy," "goal," "seeks," "may," "will," "expects," "intends," "believes," "should," and
similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or
events or developments that Vivani Medical, Inc. ("Vivani", the "Company", "we" or "us) expects or anticipates will occur in the future, such as stated objectives
or goals, our product candidates and their therapeutic potential and planned development, the indications that we intend to target, our technology, our
business and strategy, milestones, addressable markets, or that are not otherwise historical facts, are forward-looking statements. While management has
based any forward-looking statements included in this presentation on its current expectations, the information on which such expectations were based may
change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-
looking statements as a result of various factors. These risks and uncertainties include, but are not limited to, that we may fail to complete any required pre-
clinical activities for NPM-119 or otherwise commence our planned Phase 2 trial for this candidate; conduct any pre-clinical activities of our other product
candidates; our product candidates may not demonstrate safety or efficacy in clinical trials; we may fail to secure marketing approvals for our product
candidates; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets
of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing
treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract
and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-
parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks and uncertainties are described in
our Annual Report on Form 10-K filed on March 29, 2022, and in the Company's Forms 10-K/A filed on May 2, 2022, S-4 filed on May 13, 2022, 10-Q filed on May
16, 2022, and 10-Q filed on August 12, 2022, and as thereafter amended. We urge you to consider those risks and uncertainties in evaluating our forward-
looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except
as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-
looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or
circumstances on which any such statement is based. Certain information contained in this presentation relates to or is based on studies, publications, surveys
and other data obtained from third party sources and the Company's own internal estimates and research. While we believe these third-party sources to be
reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or
completeness of, any information obtained from third-party sources. Finally, while we believe our own internal research is reliable, such research has not been
verified by any independent source. All of our therapies are still investigational and have not been approved by any regulatory authority for any use.
2View entire presentation